IPM Take
For years, health systems treated hypertension, diabetes, chronic kidney disease and cardiovascular disease as separate problems. Patients experienced something very different. Most people at highest risk live with several of these conditions simultaneously. HEARTS 2.0 acknowledges that reality. The significance extends beyond Latin America. As health systems struggle with rising multimorbidity, integrated cardio-kidney-metabolic care is emerging as one of the defining healthcare delivery models of the decade. The winners may not be individual medicines, but the systems that learn how to connect prevention, diagnosis, risk assessment and long-term management.
Executive Summary
The Pan American Health Organization (PAHO) has launched HEARTS 2.0, an updated clinical pathway designed to integrate hypertension management with broader cardiovascular-kidney-metabolic prevention in primary care. Building on a programme already adopted in 29 countries across the Americas, the new pathway incorporates screening and management of diabetes, chronic kidney disease and cardiovascular risk within a single evidence-based framework. The initiative is supported by a multi-phase process involving intervention prioritisation, implementation readiness assessments across 26 countries and evidence review using GRADE methodology. The update reflects growing international recognition that cardiovascular, renal and metabolic diseases require coordinated prevention and management strategies rather than siloed approaches.
Why it matters
- Policymakers: Integrated cardio-kidney-metabolic care is becoming a strategic priority for tackling the growing burden of noncommunicable diseases.
- Health systems: Standardised pathways may improve prevention, treatment consistency and long-term outcomes while reducing fragmentation of care.
- Industry / innovation partners: Broader risk assessment and earlier screening may expand demand for diagnostics, digital tools and preventive therapies across multiple disease areas.
- Clinicians: Primary care is increasingly expected to manage cardiovascular, metabolic and kidney risk through a unified model rather than separate disease programmes.
Changes in cardiometabolic care are increasingly being driven by health system design rather than new medicines alone.
PAHO’s HEARTS 2.0 update is a good example. While presented as a clinical pathway for hypertension management, it reflects a broader shift towards integrating cardiovascular, kidney and metabolic care within primary care settings.
PAHO’s launch of HEARTS 2.0 may appear at first glance to be a routine update to a hypertension management pathway. In reality, it signals something much larger.
The era of treating cardiovascular disease, diabetes and chronic kidney disease as separate conditions is beginning to end.
The new pathway maintains hypertension as the entry point to prevention but expands its scope to include cardiovascular, kidney and metabolic risk assessment, screening and management within a single primary care framework.
This matters because the traditional disease-by-disease model increasingly fails to reflect clinical reality.
Patients with hypertension frequently have diabetes. Patients with diabetes frequently develop chronic kidney disease. Cardiovascular risk cuts across all three.
Yet health systems often continue to organise services, funding streams and clinical pathways as if these conditions exist independently.
HEARTS 2.0 attempts to bridge that gap.
The updated model includes standardised blood pressure diagnosis, cardiovascular-kidney-metabolic risk assessment, simplified treatment protocols, essential medicine recommendations and structured follow-up pathways.
Importantly, it is not simply a clinical guideline. It is an implementation strategy.
PAHO’s development process included assessment of real-world readiness across 26 countries, recognising that evidence alone does not improve outcomes if health systems cannot deliver it.
That distinction is becoming increasingly important.
Many countries already possess clinical guidelines for hypertension, diabetes and chronic kidney disease. The challenge is translating those recommendations into routine primary care practice at scale.
The emergence of cardio-kidney-metabolic medicine reflects a broader trend visible across global healthcare.
Major cardiovascular and diabetes societies are increasingly discussing CKM syndrome as a continuum rather than a collection of separate diseases. New generations of therapies, including SGLT2 inhibitors, GLP-1 receptor agonists and emerging multi-pathway treatments, are also blurring traditional disease boundaries.
The policy implications are substantial.
Health systems designed around single-disease programmes may struggle to manage patients whose risks span multiple specialties simultaneously.
For industry, the shift is equally important.
Integrated pathways create opportunities for earlier screening, broader risk stratification and more coordinated use of diagnostics, digital monitoring tools and preventive therapies. They also create pressure for stronger evidence demonstrating benefits across cardiovascular, renal and metabolic outcomes simultaneously.
For IPM, HEARTS 2.0 represents something larger than a guideline update.
It is a signal that cardiometabolic care is entering a new phase.
The future may belong less to individual disease programmes and more to integrated models capable of managing the complex reality of chronic disease in ageing populations.
